<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057069</url>
  </required_header>
  <id_info>
    <org_study_id>M09TNM</org_study_id>
    <secondary_id>2009-015238-31</secondary_id>
    <nct_id>NCT01057069</nct_id>
  </id_info>
  <brief_title>Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer</brief_title>
  <acronym>neo-TN</acronym>
  <official_title>Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the response of triple-negative breast cancer with deficient
      homologous recombination to intensified alkylating chemotherapy versus standard chemotherapy
      with dose dense AC and/or Docetaxel-Capecitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Homologous Recombination (HR) is a DNA repair mechanism that can repair double-strand DNA
      breaks. It is the only reliable repair mechanism that can repair the consequences of DNA
      adducts caused by bifunctional alkylating agents (such as cyclophosphamide, thiotepa or
      carboplatin). Alternative DNA repair mechanisms exist, but these unavoidably induce DNA
      mutations, deletions and chromosome aberrations, giving give rise to genetic instability. HRD
      may be a consequence of inactivation of the BRCA-1 or BRCA-2 genes (as in hereditary breast
      cancer), but it may also be caused by defects in the Fanconi anemia pathway or by
      amplification of the EMSY gene. HRD is present in breast cancer cells but not in healthy
      cells of BRCA-1 or BRCA-2 mutation carriers, and also in about half of the sporadic
      triple-negative breast cancers.

      This phase II/III controlled multicenter trial will investigate the ability of individualized
      chemotherapy to improve the objective response rate of 'triple-negative' breast cancer
      (estrogen receptor and progesterone receptor-negative, no HER2 amplification) to preoperative
      (neoadjuvant) chemotherapy. It will answer the question whether intensified alkylating
      chemotherapy improves the response rate of tumors with a Homologous Recombination Defect
      (HRD) and it will gather data required for the design of a phase III study documenting the
      efficacy of response monitoring by contrast-enhanced MRI in TN breast cancer without HRD.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint (HRD tumors): Average Neoadjuvant Response Index (NRI) after intensified alkylating therapy in comparison to that after 'standard' neoadjuvant chemotherapy. Primary endpoint (non-HRD tumors): Average Neoadjuvant Response Index (NRI)</measure>
    <time_frame>end of neo adjuvant chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival and overall survival.</measure>
    <time_frame>every year</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HRD; 1x ddAC, 2x tCTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRD; 3x CP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HRD tumors; any response to 3x ddAC; 3 courses of CP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-HRD;3x CP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-HRD; response; 3x ddAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-HRD; response; 3x CP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin and Paclitaxel</intervention_name>
    <description>Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations</description>
    <arm_group_label>HRD; 3x CP</arm_group_label>
    <arm_group_label>non-HRD;3x CP</arm_group_label>
    <arm_group_label>non-HRD; response; 3x CP</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin, cyclophosphamide</intervention_name>
    <description>Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.</description>
    <arm_group_label>non-HRD; response; 3x ddAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide</intervention_name>
    <description>One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.</description>
    <arm_group_label>HRD; 1x ddAC, 2x tCTC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proven infiltrating breast cancer with either a primary tumor over 2 cm in size (MRI
             or ultrasound examination) and/or cytologically proven spread to the axillary lymph
             nodes.

          -  Patients with 'locally advanced breast cancer' are consequently eligible, including
             those with ipsilateral supraclavicular lymph node metastases.

          -  The tumor must be HER2/neu-negative (either score 0 or 1 at immunohistochemistry or
             negative at in situ hybridization [CISH or FISH] in case of score 2 or 3 at
             immunohistochemistry).

          -  The tumor must be Estrogen receptor (ER) -negative (&lt; 10% nuclear staining at IHC) and
             Progesterone receptor (PR) -negative (&lt; 10% nuclear staining at IHC). However, the
             rare tumors that are ER-negative and PR-positive will be eligible, if this pattern of
             hormone receptor expression can be verified in the NKI-AVL reference pathology lab.

          -  Age 18 to 59 years; patients older than 59 years may be included when considered
             'biologically 59 years or younger' (as judged by the investigator).

          -  Performance status: WHO 0 or I.

          -  Adequate bone marrow function (W.B.C. count &gt; 3.0 x 109/l, platelets &gt; 100 x 109/l).

          -  Adequate hepatic function (ALAT, ASAT and bilirubin &lt; 2 x upper limit of normal, or
             minor abnormalities of these tests judged to be of no consequence by the study
             coordinator).

          -  Adequate renal function (creatinine clearance &gt; 60 ml/min).

          -  Informed consent

        Exclusion Criteria:

          -  Previous radiation therapy or chemotherapy.

          -  Other malignancy except carcinoma in situ, unless the other malignancy was treated 5
             or more years ago with curative intent without the use of chemotherapy or radiation
             therapy.

          -  Pregnancy or breast feeding.

          -  Evidence of distant metastases. Staging examinations must have included a chest
             roentgenogram, an ultrasound examination of the liver and an isotope bone scan.
             Abnormal uptake on the isotope bone scan can only be accepted if bone metastases were
             excluded by MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sjoerd Rodenhuis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Groep</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <zip>2501 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7400 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <zip>2000AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum Parkstad</name>
      <address>
        <city>Heerlen</city>
        <zip>6401 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2130 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3007 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Rodenhuis S, Mandjes IA, Wesseling J, van de Vijver MJ, Peeters MJ, Sonke GS, Linn SC. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol. 2010 Mar;21(3):481-7. doi: 10.1093/annonc/mdp348. Epub 2009 Aug 28.</citation>
    <PMID>19717533</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neo adjuvant</keyword>
  <keyword>Triple negative</keyword>
  <keyword>primary tumor over 2 cm and/or positive lymphnodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

